Literature DB >> 10708863

Tissue inhibitors of metalloproteinases: evolution, structure and function.

K Brew1, D Dinakarpandian, H Nagase.   

Abstract

The matrix metalloproteinases (MMPs) play a key role in the normal physiology of connective tissue during development, morphogenesis and wound healing, but their unregulated activity has been implicated in numerous disease processes including arthritis, tumor cell metastasis and atherosclerosis. An important mechanism for the regulation of the activity of MMPs is via binding to a family of homologous proteins referred to as the tissue inhibitors of metalloproteinases (TIMP-1 to TIMP-4). The two-domain TIMPs are of relatively small size, yet have been found to exhibit several biochemical and physiological/biological functions, including inhibition of active MMPs, proMMP activation, cell growth promotion, matrix binding, inhibition of angiogenesis and the induction of apoptosis. Mutations in TIMP-3 are the cause of Sorsby's fundus dystrophy in humans, a disease that results in early onset macular degeneration. This review highlights the evolution of TIMPs, the recently elucidated high-resolution structures of TIMPs and their complexes with metalloproteinases, and the results of mutational and other studies of structure-function relationships that have enhanced our understanding of the mechanism and specificity of the inhibition of MMPs by TIMPs. Several intriguing questions, such as the basis of the multiple biological functions of TIMPs, the kinetics of TIMP-MMP interactions and the differences in binding in some TIMP-metalloproteinase pairs are discussed which, though not fully resolved, serve to illustrate the kind of issues that are important for a full understanding of the interactions between families of molecules.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708863     DOI: 10.1016/s0167-4838(99)00279-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  425 in total

Review 1.  That impish TIMP: the tissue inhibitor of metalloproteinases-3.

Authors:  J F Woessner
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

2.  Morphological and molecular characterization of human hamstrings shows that tendon features are not influenced by donor age.

Authors:  Nicoletta Gagliano; Alessandra Menon; Federico Cabitza; Riccardo Compagnoni; Pietro Randelli
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-08-02       Impact factor: 4.342

3.  Remodeling in vein expresses arterial phenotype in hyperhomocysteinemia.

Authors:  Poulami Basu; Natia Qipshidze; Suresh C Tyagi; Utpal Sen
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-11-15

4.  Moderate joint loading reduces degenerative actions of matrix metalloproteinases in the articular cartilage of mouse ulnae.

Authors:  Hui B Sun; Liming Zhao; Shigeo Tanaka; Hiroki Yokota
Journal:  Connect Tissue Res       Date:  2011-12-07       Impact factor: 3.417

5.  Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets.

Authors:  Anna Radomski; Paul Jurasz; Esmond J Sanders; Christopher M Overall; Heather F Bigg; Dylan R Edwards; Marek W Radomski
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 6.  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.

Authors:  Klaus Maskos; Wolfram Bode
Journal:  Mol Biotechnol       Date:  2003-11       Impact factor: 2.695

Review 7.  Matrix metalloproteinase inhibitors.

Authors:  Nithya Ramnath; Patrick J Creaven
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

8.  Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation.

Authors:  Neel R Sodha; Richard T Clements; Munir Boodhwani; Shu-Hua Xu; Roger J Laham; Cesario Bianchi; Frank W Sellke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-12-12       Impact factor: 4.733

9.  Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction.

Authors:  Shaina R Eckhouse; Brendan P Purcell; Jeremy R McGarvey; David Lobb; Christina B Logdon; Heather Doviak; Jason W O'Neill; James A Shuman; Craig P Novack; Kia N Zellars; Sara Pettaway; Roy A Black; Aarif Khakoo; Taeweon Lee; Rupak Mukherjee; Joseph H Gorman; Robert C Gorman; Jason A Burdick; Francis G Spinale
Journal:  Sci Transl Med       Date:  2014-02-12       Impact factor: 17.956

Review 10.  Metalloproteinases and plasminogen activators in vessel remodeling.

Authors:  Alex Bobik; Vselovod Tkachuk
Journal:  Curr Hypertens Rep       Date:  2003-12       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.